The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial
Open accessAbstract
Importance: Extended-spectrum β-lactamases mediate resistance to third-generation cephalosporins (eg, ceftriaxone) in Escherichia coli and Klebsiella pneumoniae. Significant infections caused by these strains are usually treated with carbapenems, potentially selecting for carbapenem resistance. Piperacillin-tazobactam may be an effective "carbapenem-sparing" option to treat extended-spectrum β-lactamase producers. Objectives: To determine whether definitive therapy with piperacillin-tazobactam is noninferior to meropenem (a carbapenem) in patients with bloodstream infection caused by ceftriaxone-nonsusceptible E coli or K pneumoniae. Design, Setting, and Participants: Noninferiority, parallel group, randomized clinical trial included hospitalized patients enrolled from 26 sites in 9 countries from February 2014 to July 2017. Adult patients were eligible if they had at least 1 positive blood culture with E coli or Klebsiella spp testing nonsusceptible to ceftriaxone but susceptible to piperacillin-tazobactam. Of 1646 patients screened, 391 were included in the study. Interventions: Patients were randomly assigned 1:1 to intravenous piperacillin-tazobactam, 4.5 g, every 6 hours (n = 188 participants) or meropenem, 1 g, every 8 hours (n = 191 participants) for a minimum of 4 days, up to a maximum of 14 days, with the total duration determined by the treating clinician. Main Outcomes and Measures: The primary outcome was all-cause mortality at 30 days after randomization. A noninferiority margin of 5% was used. Results: Among 379 patients (mean age, 66.5 years; 47.8% women) who were randomized appropriately, received at least 1 dose of study drug, and were included in the primary analysis population, 378 (99.7%) completed the trial and were assessed for the primary outcome. A total of 23 of 187 patients (12.3%) randomized to piperacillin-tazobactam met the primary outcome of mortality at 30 days compared with 7 of 191 (3.7%) randomized to meropenem (risk difference, 8.6% [1-sided 97.5% CI, -∞ to 14.5%]; P = .90 for noninferiority). Effects were consistent in an analysis of the per-protocol population. Nonfatal serious adverse events occurred in 5 of 188 patients (2.7%) in the piperacillin-tazobactam group and 3 of 191 (1.6%) in the meropenem group. Conclusions and relevance: Among patients with E coli or K pneumoniae bloodstream infection and ceftriaxone resistance, definitive treatment with piperacillin-tazobactam compared with meropenem did not result in a noninferior 30-day mortality. These findings do not support use of piperacillin-tazobactam in this setting. Trial Registration: anzctr.org.au Identifiers: ACTRN12613000532707 and ACTRN12615000403538 and ClinicalTrials.gov Identifier: NCT02176122.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
Self-citationCharlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
APACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Performance standards for antimicrobial susceptibility testing
Weinstein, M. P., & Clinical (2019) · Clinical and Laboratory Standards Institute eBooks · Cited by 4,341
Seymour, C. W., Liu, V. X., Iwashyna, T. J., Brunkhorst, F. M., Rea, T. D., Scherag, A., Rubenfeld, G., Kahn, J. M., Shankar-Hari, M., Singer, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0288 · Cited by 3,939
Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,491
Self-citationMultiple imputation of discrete and continuous data by fully conditional specification
van Buuren, S. (2007) · Statistical Methods in Medical Research · doi:10.1177/0962280206074463 · Cited by 2,827
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
Pitout, J. D., & Laupland, K. B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70041-0 · Cited by 2,044
The PRECIS-2 tool: designing trials that are fit for purpose
Loudon, K., Treweek, S., Sullivan, F., Donnan, P., Thorpe, K. E., & Zwarenstein, M. (2015) · BMJ · doi:10.1136/bmj.h2147 · Cited by 1,846
Hospital-Acquired Infections Due to Gram-Negative Bacteria
Peleg, A. Y., & Hooper, D. C. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0904124 · Cited by 1,495
Self-citationHiggins (2002) · doi:10.1002/(issn)1097-0258 · Cited by 1,248
Comparative analysis of two rates
Miettinen, O., & Nurminen, M. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040211 · Cited by 1,110
Sample Size Calculations in Clinical Research
Chow, S.-C., Wang, H., & Shao, J. (2003) · CRC Press eBooks · doi:10.1201/9780203911341 · Cited by 807
Sample Size Calculations in Clinical Research
Chow, S.-C., Wang, H., & Shao, J. (2007) · doi:10.1201/9781584889830 · Cited by 562
Rodriguez-Bano, J., Navarro, M. D., Retamar, P., Picon, E., Pascual, A., & the Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa/Grupo de Estudio de Infeccion Hospitalaria Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir790 · Cited by 363
Vardakas, K. Z., Tansarli, G. S., Rafailidis, P. I., & Falagas, M. E. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks301 · Cited by 354
Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary
Chow, J. W., & Yu, V. L. (1999) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(98)00060-0 · Cited by 320
Tamma, P. D., Han, J. H., Rock, C., Harris, A. D., Lautenbach, E., Hsu, A. J., Avdic, E., & Cosgrove, S. E. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ003 · Cited by 314
Kaye, K. S., Bhowmick, T., Metallidis, S., Bleasdale, S. C., Sagan, O. S., Stus, V., Vazquez, J., Zaitsev, V., Bidair, M., Chorvat, E., et al. (2018) · JAMA · doi:10.1001/jama.2018.0438 · Cited by 314
Doi, Y., Park, Y. S., Rivera, J. I., Adams-Haduch, J. M., Hingwe, A., Sordillo, E. M., Lewis, J. S., Howard, W. J., Johnson, L. E., Polsky, B., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis942 · Cited by 303
Self-citationHarris, P. N. A., Tambyah, P. A., & Paterson, D. L. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70950-8 · Cited by 198
Self-citationCorrelations of Antibiotic Use and Carbapenem Resistance in Enterobacteriaceae
McLaughlin, M., Advincula, M. R., Malczynski, M., Qi, C., Bolon, M., & Scheetz, M. H. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00607-13 · Cited by 191
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections
Tamma, P. D., & Rodriguez-Baňo, J. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix034 · Cited by 186
Gutiérrez‐Gutiérrez, B., Pérez-Galera, S. I., Salamanca, E., de Cueto, M., Calbo, E., Almirante, B., Viale, P., Oliver, A., Pintado, V., Gasch, O., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00365-16 · Cited by 167
Self-citationNg, T. M., Khong, W. X. L., Harris, P. N. A., De, P. P., Chow, A. L., Tambyah, P. A., & Lye, D. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153696 · Cited by 140
Self-citationJohnson, J. R., Urban, C. M., Weissman, S. J., Jorgensen, J. H., Lewis, J. S., Hansen, G. T., Edelstein, P. H., Robicsek, A. A., Cleary, T., Adachi, J. A., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05824-11 · Cited by 117
Self-citationAmbrose, P. G., Bhavnani, S. M., & Jones, R. N. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1643-1646.2003 · Cited by 96
Nguyen, H. M., Shier, K. L., & Graber, C. J. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt450 · Cited by 90
Harris, P. N. A., Zakour, N. L. B., Roberts, L. W., Wailan, A. M., Zowawi, H. M., Tambyah, P. A., Lye, D. C., Jureen, R., Lee, T. H., Mo, Y., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx466 · Cited by 83
Self-citationHarris, P. N. A., Peleg, A. Y., Iredell, J. R., Ingram, P. R., Miyakis, S., Stewardson, A. J., Rogers, B. A., McBryde, E. S., Roberts, J. A., Lipman, J., et al. (2015) · Trials · doi:10.1186/s13063-014-0541-9 · Cited by 82
Self-citationGart, J. J., & Nam, J. (1990) · Biometrics · doi:10.2307/2532084 · Cited by 72
Sugumar, M., Kumar, K. M., Manoharan, A., Anbarasu, A., & Ramaiah, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091800 · Cited by 67
Inhibition of OXA-1 β-Lactamase by Penems
Bethel, C. R., Distler, A. M., Ruszczycky, M. W., Carey, M. P., CAREY, P. R., Hujer, A. M., Taracila, M., Helfand, M. S., Thomson, J. M., Kalp, M., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01677-07 · Cited by 33
Cited by
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Self-citationTamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Paul, M., Carrara, E., Retamar, P., Tängdén, T., Bitterman, R., Bonomo, R. A., de Waele, J., Daikos, G. L., Akova, M., Harbarth, S., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.025 · Cited by 1,056
Self-citationVentilator-associated pneumonia in adults: a narrative review
Papazian, L., Klompas, M., & Luyt, C.-E. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05980-0 · Cited by 1,010
Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection
Castanheira, M., Simner, P. J., & Bradford, P. A. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab092 · Cited by 796
Metadata
- Authors
- Harris, P. N. A., Tambyah, P. A., Lye, D. C., Mo, Y., Lee, T. H., Yilmaz, M., Alenazi, T. H., Arabi, Y., Falcone, M., Bassetti, M., Righi, E., Rogers, B. A., Kanj, S., Bhally, H., Iredell, J., Mendelson, M., Boyles, T. H., Looke, D., Miyakis, S., Walls, G., Al Khamis, M., Zikri, A., Crowe, A., Ingram, P., Daneman, N., Griffin, P., Athan, E., Lorenc, P., Baker, P., Roberts, L., Beatson, S. A., Peleg, A. Y., Harris-Brown, T., Paterson, D. L., & for the MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN)
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2018-09-11
- Volume
- 320
- Issue
- 10
- Pages
- 984
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2892368225
- Cited by
- 774
- References
- 37
- FWCI
- 29.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.